Disitamab vedotin plus SOX versus SOX alone as adjuvant treatment for HER2-moderate/high stage III gastric cancer after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized phase II trial compares disitamab vedotin (RC48) combined with the SOX chemotherapy regimen versus SOX alone as postoperative adjuvant therapy for patients with HER2-moderate/high stage III gastric or gastroesophageal junction adenocarcinoma who had D2 or wider lymph node dissection and R0 resection. Participants begin adjuvant therapy about four weeks after surgery and receive 6–8 cycles, with imaging every three months to monitor for recurrence and survival follow-up every three months after recurrence. Safety assessments continue from the first dose until 60 days after the last dose or the start of new anti-tumor therapy. Eligible patients must be 18–75 years old, have HER2 IHC 2+ or 3+, ECOG 0–1, adequate organ function, and no prior systemic anti-tumor therapy before surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged between 18 and 75 years.
* Have undergone radical resection with D2 or wider lymph node dissection and achieved R0 resection status.
* No prior systemic anti-tumor treatment (i.e., neoadjuvant therapy) before surgery.
* Histopathologically confirmed gastric adenocarcinoma.
* Pathological stage III gastric and gastroesophageal junction adenocarcinoma patients (according to the 8th edition of the American Joint Committee on Cancer \[AJCC\] staging system).
* HER2 moderate-to-high expression (IHC 3+ or 2+).
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
* Expected survival time ≥ 3 months.
* Able to understand the study protocol, voluntarily participate in the study, and provide written informed consent;
* Good compliance and able to cooperate with the treatment regimen specified in this study;
* Possesses complete imaging and pathological clinical data;
* Adequate organ and bone-marrow function.

Exclusion Criteria:

* Primary stage III gastric or gastroesophageal-junction adenocarcinoma not histologically or cytologically confirmed;
* Unable to receive disitamab vedotin or SOX chemotherapy;
* Unable to comply with the required follow-up schedule;
* Unable to accept the treatment regimen specified in this protocol;
* Unable or unwilling to undergo mandated response assessments (e.g., CT imaging);
* Active autoimmune disease;
* History of psychoactive-substance abuse that cannot be discontinued, or any severe/uncontrolled psychiatric disorder, or any severe/uncontrolled systemic disease;
* Any concomitant condition that, in the investigator's opinion, poses significant risk to the subject or could compromise study completion;
* Other malignancies within 5 years before screening, except adequately treated cancers considered cured (e.g., thyroid cancer, cervical carcinoma in situ, basal/squamous-cell skin cancer, or ductal carcinoma in situ of the breast treated with curative surgery);
* Lactating women;
* Prior neoadjuvant therapy or intra-operative intraperitoneal chemotherapy.

Where it's running

• The First Affiliated Hospital with Nanjing Medical University
  Nanjing, Jiangsu, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• A combination therapy for advanced second-line gastric cancer using apatinib with albumin-bound paclitaxel, with or without adebrelimab

  This study tests whether adding adebrelimab to a regimen of apatinib and albumin-bound paclitaxel helps patients with advanced gastric or gastroesophageal junction cancer who did not respond to first-line therapy.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT07770113

• Disitamab Vedotin Plus Radiotherapy for HER2-Expressing Upper Tract Urothelial Carcinoma After Surgery

  This study tests whether disitamab vedotin with radiotherapy can improve outcomes for people with HER2-expressing upper tract urothelial carcinoma after radical surgery who can’t receive cisplatin.

  Recruiting Phase 3 Peking University First Hospital · Beijing · NCT07498907

• Disitamab vedotin plus bevacizumab for HER2-low metastatic breast cancer after T‑DxD failure

  This study will try disitamab vedotin combined with bevacizumab in adults with HER2‑low metastatic breast cancer whose disease progressed after trastuzumab deruxtecan.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07446452

• Disitamab vedotin plus trastuzumab and tislelizumab versus chemotherapy plus trastuzumab (± pembrolizumab) for HER2‑high advanced gastric or gastroesophageal junction adenocarcinoma

  This trial tests whether combining disitamab vedotin with trastuzumab and the immunotherapy tislelizumab works better than standard chemotherapy with trastuzumab (with or without pembrolizumab) as first‑line treatment for people with HER2‑high advanced gastric or gastroesophageal junction cancer.

  Recruiting Phase 3 RemeGen Co., Ltd. · Beijing, BJ-Beijing · NCT07315750

• Disitamab vedotin plus carboplatin and bevacizumab as first-line and maintenance treatment for HER2-expressing, HRD-negative high-risk ovarian cancer

  This study tests whether adding disitamab vedotin to carboplatin and bevacizumab helps people with HER2-expressing, HRD-negative high-risk ovarian cancer as first-line and maintenance treatment.

  Recruiting Phase 2 Jiangsu Cancer Institute & Hospital · Nanjing, Jiangsu and 1 other locations · NCT07311577

• Disitamab Vedotin plus BCG vs BCG alone in HER2-expressing high-risk NMIBC

  This study tests whether adding disitamab vedotin to BCG helps people with early, high-risk bladder cancer that hasn’t spread outside the bladder.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07207824

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.